Samuel L Aitken

University of Michigan — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index5.2kcitations195works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotic Resistance in Bacteria(55), Antibiotics Pharmacokinetics and Efficacy(38), Bacterial Identification and Susceptibility Testing(30), Antibiotic Use and Resistance(29), Neutropenia and Cancer Infections(26)

Publications180 total

Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
UNC Libraries·2026Open Access
The role of uridine diphosphate glucuronosyltransferase 1A4 polymorphisms on posaconazole exposure
Pharmacogenetics and Genomics·2026
P-928. Clinical Impact of Linezolid Therapeutic Drug Monitoring on the Tolerability of Prolonged Courses in the Outpatient Setting
Open Forum Infectious Diseases·2026Open Access
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in <i>Pseudomonas aeruginosa</i>
Clinical Infectious Diseases·2025· 2 cited
Effect of Medications on Fluid, Fat and Muscle Composition in Patients With Chronic Heart Failure
Heart Lung and Circulation·2025Open Access
Impact of Comorbidities on Fluid, Fat And Muscle Composition in Patients Attending a Quaternary Heart Failure Clinic
Heart Lung and Circulation·2025
How do I manage a patient with Stenotrophomonas maltophilia infection?
Clinical Microbiology and Infection·2025· 9 cited
Antimicrobial Stewardship and Beyond: The Many Essential Roles of Infectious Diseases Pharmacists
Clinical Infectious Diseases·2025· 5 cited
Crushed Posaconazole Delayed-Release Tablets Have Reduced Bioavailability and Interaction with Tacrolimus Relative to Other Administration Routes
The Journal of Heart and Lung Transplantation·2025
312. Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) <i>Pseudomonas aeruginosa</i> infections in the United States (CACTUS)
Open Forum Infectious Diseases·2025Open Access
311. Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for multidrug-resistant (MDR) <i>Pseudomonas aeruginosa</i> infections in the United States (CACTUS)
Open Forum Infectious Diseases·2025Open Access
P-639. Development of antimicrobial resistance in patients with pneumonia due to <i>P.aeruginosa</i> treated with cefepime or piperacillin-tazobactam
Open Forum Infectious Diseases·2025Open Access
Cytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib
Journal of Oncology Pharmacy Practice·2024· 3 cited
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
The Lancet Infectious Diseases·2024· 39 cited
A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Pneumonia Caused by Gram-Negative Bacteria in Intensive Care Units: Unit-Specific Combination Antibiograms Versus Patient-Specific Risk Factors
Open Forum Infectious Diseases·2024· 2 citedOpen Access
Implementation of an Automated Antibiotic Time-out at a Comprehensive Cancer Center
Open Forum Infectious Diseases·2024· 3 citedOpen Access
The Growing Threat of NDM-Producing <i>Escherichia coli</i> With Penicillin-Binding Protein 3 Mutations in the United States—Is There a Potential Role for Durlobactam?
Clinical Infectious Diseases·2024· 14 citedOpen Access
Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185
mBio·2024· 13 citedOpen Access
A Multicenter, Observational Study to Compare the Effectiveness of Ceftazidime-Avibactam Versus Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas Aeruginosa Infections in the United States (Cactus)
SSRN Electronic Journal·2024Open Access
A novel 2-step process for the management of inpatient beta-lactam allergy labels
Annals of Allergy Asthma & Immunology·2023
page 1 of 9Next →

Frequent Co-authors

Samuel A. Shelburne(13), César A. Arias(11), Robert A. Bonomo(7), David van Duin(7), Kevin W. Garey(7), Pranita D. Tamma(6), Amy J. Mathers(6), José M. Munita(6), Truc T. Tran(6), Micah M. Bhatti(6), Cornelius J. Clancy(5), Roy F. Chemaly(5), Pranoti Sahasrabhojane(5), Lilian M. Abbo(4), Frank Tverdek(4), Dimitrios P. Kontoyiannis(4), Dhara N. Shah(4), Federico Pérez(3), Farnaz Foolad(3), Terri Lynn Shigle(3)